Position in NVO
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$216,976
+$50,646 QoQ
Shares Held
4,526
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,003
of 1,348 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FOSTER DYKEMA CABOT & PARTNERS, LLC holds $37,893,315 across 11 Drug Manufacturers - General names. NVO ranks #5 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
28,025 | $33,614,028 | |
| 2 | JNJ |
Johnson & Johnson
|
5,153 | $1,308,707 | |
| 3 | MRK |
Merck & Co., Inc.
|
8,626 | $1,108,441 | |
| 4 | ABBV |
AbbVie Inc.
|
3,815 | $960,006 | |
| 5 | NVO |
Novo Nordisk A S
This page
|
4,526 | $216,976 | |
| 6 | NVS |
Novartis AG
|
1,094 | $171,451 | |
| 7 | AZN |
Astrazeneca PLC
|
820 | $155,488 | |
| 8 | AMGN |
Amgen Inc
|
420 | $152,090 |
All Filings in NVO
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $216,976 | 4,526 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $166,330 | 4,526 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $230,282 | 4,526 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $251,147 | 4,526 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $312,384 | 4,526 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $314,285 | 4,526 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $375,047 | 4,360 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $522,479 | 4,388 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $441,066 | 3,090 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $396,756 | 3,090 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $319,660 | 3,090 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||